No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
92 |
4. Check minimum number of eventsNone |
92 |
5. Include endpointsNone |
92 |
6. Filter based on genotype QC (FinnGen only) |
80 |
Control definitions (FinnGen only)
- Control exclude
- N14_GLOMERULAR
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- N00-N08
- Name in latin
- Syndroma nephriticum cito progrediens
Similar endpoints
↥List of similar endpoints to
Rapidly progressive nephritic syndrome
based on the number of shared cases.
Similar with more cases:
- Glomerulonephritis
- Glomerular diseases
- All kidney diseases
- Genitourinary diseases
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 618 | 323 | 291 |
| Only index persons | 464 | 246 | 218 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 58.72 | 58.87 | 58.31 |
| Only index persons | 52.82 | 52.51 | 53.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 80 | 38 | 42 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 55.92 | 48.02 | 63.06 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 83
- Matched controls
- 830
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
26.9
44.5
36
23
N01.9
ICD-10 Finland
Rapidly progressive nephritic syndrome, unspecified
+∞
36.1
32
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
84.3
32.6
35
7
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
102.0
30.6
32
5
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
218.9
29.8
29
*
H02AB04
ATC
methylprednisolone; systemic
12.4
28.5
38
53
L04AX01
ATC
azathioprine; systemic
36.2
22.8
29
12
A11CC03
ATC
alfacalcidol; systemic
66.4
21.5
24
5
TK800
NOMESCO Finland
Hemodialysis
50.1
21.3
25
7
L04AA06
ATC
mycophenolic acid; systemic
138.5
20.6
21
*
A12AA04
ATC
calcium carbonate; oral
73.6
20.1
22
*
127
Kela drug reimbursment
Transplant complication
129.9
19.5
20
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
69.1
19.0
21
*
N18.8
ICD-10 Finland
Other chronic renal failure
39.0
18.6
23
8
C03CA01
ATC
furosemide; systemic
7.2
17.8
56
185
Z94.0
ICD-10 Finland
Kidney transplant status
80.8
17.6
19
*
B03XA02
ATC
darbepoetin alfa; parenteral
48.4
16.2
19
5
N18.0
ICD-10 Finland
End-stage renal disease
195.3
16.1
16
*
137
Kela drug reimbursment
Uraemia requiring dialysis
195.3
16.1
16
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
16.6
16.0
26
22
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
70.2
15.4
17
*
N01.7
ICD-10 Finland
Rapidly progressive nephritic syndrome, diffuse crescentic glomerulonephritis
+∞
15.0
14
*
N17.9
ICD-10 Finland
Acute renal failure, unspecified
20.8
15.0
22
14
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
7.4
14.9
27
51
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.7
14.4
30
65
V03AE01
ATC
polystyrene sulfonate; oral
65.1
14.4
16
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
12.7
13.7
25
27
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
48.7
13.7
16
*
N19
ICD-10 Finland
Unspecified kidney failure
17.1
13.3
21
16
L04AD01
ATC
ciclosporin; systemic
60.2
13.3
15
*
205
Kela drug reimbursment
Chronic hypertension
5.0
12.1
42
141
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
138.4
11.7
12
*
N01.1
ICD-10 Finland
Rapidly progressive nephritic syndrome, focal and segmental glomerular lesions
+∞
11.7
11
*
KA1AE
NOMESCO Finland
Kidney ultrasound examination
30.0
11.6
15
6
TPX10
NOMESCO Finland
Implantation of vascular injection port
21.6
11.3
16
9
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.6
10.9
47
183
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
69.2
10.9
12
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
10.6
10
*
B03XA01
ATC
erythropoietin; parenteral
30.4
10.2
13
5
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
9.8
9.9
20
26
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
112.3
9.6
10
*
L01AA01
ATC
cyclophosphamide; systemic
+∞
9.6
9
*
B05DB
ATC
Hypertonic solutions
+∞
9.6
9
*
L04AA01
ATC
[U] ciclosporin
41.7
9.3
11
*
M04AA01
ATC
allopurinol; systemic
4.7
9.0
26
73
TPH04
NOMESCO Finland
Cathetrisation of vein
4.3
8.9
31
101
R50.9
ICD-10 Finland
Fever, unspecified
4.4
8.6
28
86
B05DA
ATC
Isotonic solutions
99.8
8.6
9
*
Z49.0
ICD-10 Finland
Preparatory care for dialysis
99.8
8.6
9
*
N08.5*M31.0
ICD-10 Finland
Glomerular disorders in Goodpasture's syndrome
+∞
8.5
8
*
TJA33
NOMESCO Finland
Percutaneous introduction of peritoneal dialysis catheter
+∞
8.5
8
*
N04.1
ICD-10 Finland
Nephrotic syndrome, focal and segmental glomerular lesions
+∞
8.5
8
*
N08.5*M31.3
ICD-10 Finland
Glomerular disorders in Wegener's granulomatosis
+∞
8.5
8
*
N08.5
ICD-10 Finland
Glomerular disorders in systemic connective tissue disorders
+∞
8.5
8
*
N01.3
ICD-10 Finland
Rapidly progressive nephritic syndrome, diffuse mesangial proliferative glomerulonephritis
+∞
8.5
8
*
J01MA14
ATC
moxifloxacin; systemic
5.5
8.1
18
40
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.8
7.8
21
55
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.3
7.8
17
25
V03AE02
ATC
sevelamer; oral
87.6
7.5
8
*
Z49.2
ICD-10 Finland
Other dialysis
87.6
7.5
8
*
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
87.6
7.5
8
*
N08.2*D89.80
ICD-10 Finland
Immunoglobulin A (IgA) nephropathy
+∞
7.4
7
*
M31.3
ICD-10 Finland
Wegener granulomatosis
+∞
7.4
7
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
7.4
7
*
N04.9
ICD-10 Finland
Nephrotic syndrome, unspecified
+∞
7.4
7
*
C08CA02
ATC
felodipine; oral
5.2
7.4
17
39
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
7.3
54
283
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.1
6.9
23
71
L04AD02
ATC
tacrolimus; systemic
43.8
6.9
8
*
B01AA03
ATC
warfarin; systemic
3.8
6.8
27
94
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.1
6.7
18
36
C08CA01
ATC
amlodipine; oral
3.3
6.6
46
228
H02AB06
ATC
prednisolone; systemic
3.4
6.5
54
296
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
75.4
6.5
7
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
12.5
6.5
11
10
N01.8
ICD-10 Finland
Rapidly progressive nephritic syndrome, other
+∞
6.3
6
*
PBM10
NOMESCO Finland
Closure of arteriovenous fistula of radial artery
+∞
6.3
6
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
9.8
6.3
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
17
8
26.23
12.62
1.8
1.1
—
—
—
0
0
19
14
17.17
12.19
2.3
1.3
0.27
0.24
g/l
0.56
19
14
19
14
17.17
12.19
2.3
1.4
1.18
1.23
g/l
0.22
19
14
11
0
+∞
11.73
3.2
0.0
—
—
—
0
0
15
12
14.93
9.30
9.0
3.8
13.65
11.86
pmol/l
0.11
15
12
62
339
4.28
8.20
47.7
7.9
1.21
1.21
mmol/l
0.09
53
294
24
72
4.28
7.53
27.3
3.5
1.23
1.54
mmol/l
0.16
24
58
18
46
4.72
6.86
5.8
3.5
44.10
68.12
ml/min/173m2
—
10
17
9
5
19.91
6.42
1.8
1.6
—
—
—
0
0
11
12
10.36
6.00
2.3
1.2
—
—
—
0
0
18
52
4.14
5.84
3.2
1.5
—
—
—
0
0
9
8
12.42
5.43
1.3
1.3
—
—
—
0
0
13
23
6.49
5.32
2.1
1.8
—
—
—
0
0
13
24
6.21
5.17
4.4
2.5
—
—
—
0
0
11
16
7.74
5.14
2.1
1.9
—
—
—
0
0
10
13
8.57
5.01
2.1
1.5
—
—
—
0
0
25
101
3.11
4.87
2.2
1.7
—
—
—
0
0
20
71
3.39
4.80
6.2
3.6
—
—
—
0
0
24
96
3.11
4.75
2.2
1.8
—
—
—
0
0
13
27
5.50
4.74
2.1
4.1
1.26
3.48
ratio
—
5
14
12
23
5.91
4.67
2.2
1.8
—
—
—
0
0
7
5
15.09
4.66
1.7
1.6
—
—
—
0
0
11
19
6.49
4.62
2.0
1.6
—
—
—
0
0
18
61
3.49
4.62
3.4
2.0
0.26
0.22
g/l
0.77
18
55
10
15
7.41
4.62
1.7
1.2
—
—
—
0
0
15
45
3.85
4.58
36.9
3.0
23.19
23.90
mmol/l
0.53
15
45
16
51
3.65
4.49
57.6
7.1
24.59
25.08
mmol/l
0.18
16
51
30
142
2.74
4.35
2.5
1.9
—
—
—
0
0
9
13
7.61
4.29
2.2
1.2
—
—
—
0
0
10
19
5.83
3.97
1.3
1.3
—
—
—
0
0
7
8
9.41
3.85
2.6
1.3
—
—
—
0
0
9
18
5.47
3.48
2.1
1.6
—
—
—
0
0
9
18
5.47
3.48
1.7
1.5
—
—
—
0
0
6
7
9.11
3.32
3.5
7.0
2108.50
446.71
mg
—
6
7
55
380
2.33
3.25
14.3
4.2
0.00
0.00
estimate
-0.00
15
79
11
30
4.06
3.23
2.3
1.7
31.65
46.90
u/l
1.33
11
24
13
45
3.24
3.19
30.2
3.1
115.00
126.18
g/l
1.52
13
45
55
383
2.29
3.14
10.3
6.6
9.16
12.54
umol/l
2.89
55
369
8
16
5.41
3.13
2.0
1.5
—
—
—
0
0
55
384
2.28
3.11
14.3
4.3
0.00
20.30
estimate
0.49
15
80
9
21
4.67
3.09
7.7
2.9
3.17
3.47
g/l
—
9
21
11
32
3.80
3.03
9.4
3.9
24.77
24.38
mmol/l
0.09
11
32
8
17
5.08
3.00
2.0
1.6
—
—
—
0
0
55
391
2.21
2.88
14.1
4.3
0.00
0.00
estimate
-0.00
13
77
7
14
5.35
2.79
2.1
1.1
—
—
—
0
0
5
6
8.76
2.78
2.4
1.3
—
—
—
0
0
9
24
4.07
2.76
2.7
2.2
8214.71
369.65
ug/l
—
9
24
14
56
2.80
2.70
22.1
4.7
1.21
1.21
mmol/l
0.23
14
50
21
105
2.34
2.60
1.3
1.2
53.34
9.41
u/ml
—
5
39
5
7
7.50
2.58
1.8
1.1
—
—
—
0
0
11
38
3.18
2.53
2.1
1.3
—
—
—
0
0
35
218
2.05
2.51
13.6
4.3
0.00
0.00
estimate
—
10
73
5
8
6.56
2.40
1.2
1.0
—
—
—
0
0
22
116
2.22
2.40
1.4
1.2
81.92
38.37
iu/ml
0.44
13
33
11
42
2.86
2.24
31.5
2.7
1.05
1.30
%
0.55
11
42
10
37
2.93
2.15
9.3
4.3
51.12
46.59
%
—
10
37
7
20
3.72
2.10
8.1
2.4
254.14
189.45
%
—
7
20
8
27
3.17
1.99
1.6
1.3
—
—
—
0
0
45
325
1.84
1.96
4.1
3.1
—
—
estimate
—
0
0
7
24
3.09
1.76
1.7
1.3
—
—
—
0
0
10
41
2.63
1.71
34.4
2.7
0.65
0.65
%
—
10
41
41
298
1.74
1.68
14.0
4.2
0.00
0.01
estimate
0.49
14
69
16
86
2.07
1.64
29.0
7.5
4.75
4.93
kpa
0.18
16
81
16
86
2.07
1.64
28.9
7.5
12.67
12.12
kpa
0.16
16
81
16
88
2.01
1.55
28.9
7.6
-0.11
0.77
mmol/l
—
10
71
10
45
2.39
1.53
2.4
1.6
—
—
—
0
0
32
222
1.72
1.51
12.7
3.5
0.00
0.01
estimate
0.49
13
68
6
22
2.86
1.46
3.7
1.2
—
—
—
0
0
6
25
2.51
1.27
9.2
2.2
103.67
96.12
%
—
6
25
13
73
1.93
1.19
1.8
2.3
31.69
26.26
u/l
0.45
13
61
5
20
2.59
1.17
2.0
1.8
—
—
—
0
0
37
282
1.56
1.15
5.9
4.4
41.41
38.91
ng/l
0.07
31
194
17
106
1.76
1.14
45.0
7.0
103.29
104.17
mmol/l
0.40
17
106
5
21
2.47
1.10
2.6
3.3
0.00
0.00
g/l
—
5
21
39
307
1.51
1.02
2.8
2.2
98.95
92.37
pmol/l
0.37
23
162
11
62
1.89
1.00
65.0
8.1
1.05
1.15
mmol/l
0.26
11
62
13
80
1.74
0.91
2.5
2.4
5.12
5.36
umol/l
0.06
13
68
6
32
1.94
0.83
2.3
2.3
—
—
—
0
0
0
25
0.00
0.80
0.0
1.6
—
—
—
0
0
5
28
1.83
0.67
2.6
1.9
—
—
—
0
0
0
21
0.00
0.61
0.0
1.9
—
—
—
0
0
23
179
1.39
0.60
4.6
2.6
—
—
—
0
0
9
59
1.59
0.57
2.3
2.3
3.63
5.99
ug/l
—
9
50
61
556
1.37
0.56
66.2
21.7
14.24
13.67
%
2.36
61
549
7
46
1.57
0.50
6.4
2.1
198.00
169.61
ng/l
—
7
41
0
17
0.00
0.41
0.0
1.5
—
1.05
—
0
11
0
17
0.00
0.41
0.0
1.5
—
1.23
—
0
11
0
17
0.00
0.41
0.0
1.5
—
0.87
—
0
11
0
18
0.00
0.40
0.0
1.4
—
52.77
—
0
18
49
451
1.21
0.32
4.0
3.3
—
—
—
0
0
16
190
0.80
0.27
3.9
4.8
23.36
23.30
%
—
8
104
71
733
0.78
0.24
76.9
26.1
124.62
133.93
g/l
4.58
71
722
11
88
1.29
0.24
1.9
2.2
—
—
—
0
0
71
732
0.79
0.22
76.3
26.0
91.69
91.05
fl
0.51
71
724
71
732
0.79
0.22
85.8
26.6
37.69
39.98
%
3.63
71
723
5
42
1.20
0.22
1.2
1.1
—
—
—
0
0
70
676
1.23
0.21
76.5
19.6
4.13
3.97
mmol/l
3.15
70
659
6
58
1.04
0.08
1.2
1.3
—
—
—
0
0
8
73
1.11
0.08
15.4
8.0
—
—
—
0
0
71
702
1.08
0.03
66.9
21.8
145.20
78.87
umol/l
6.14
71
690
12
127
0.94
0.02
1.6
1.7
—
—
—
0
0
10
94
1.07
0.01
2.0
2.4
—
—
—
0
0
18
177
1.02
0.00
1.2
1.3
1.23
1.37
u/ml
—
7
46
71
705
1.05
0.00
31.4
12.2
22.86
25.88
u/l
1.01
71
683
11
105
1.05
0.00
1.5
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.5
—
10.05
—
0
6
0
7
0.00
-0.00
0.0
2.0
—
8.01
—
0
7
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
55
0.90
-0.00
2.4
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.5
—
4.61
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
4.59
—
0
7
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
7.87
—
0
6
6
59
1.02
-0.00
2.7
2.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint N14_RAPIDPROGNEPHRITIC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_RAPIDPROGNEPHRITIC | 2.733 [1.89, 3.96] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.144 |
During the follow-up period (1.1.1998 — 31.12.2019), 78 out of 252 females with N14_RAPIDPROGNEPHRITIC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_RAPIDPROGNEPHRITIC | 3.037 [1.91, 4.83] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 98 out of 231 males with N14_RAPIDPROGNEPHRITIC died.
Mortality risk
Mortality risk for people of age
years, who have N14_RAPIDPROGNEPHRITIC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.228% | 0.493% |
| 5 | 1.488% | 3.599% |
| 10 | 3.874% | 8.098% |
| 15 | 7.352% | 15.216% |
| 20 | 12.18% | 24.741% |
Relationships between endpoints
↥Index endpoint: N14_RAPIDPROGNEPHRITIC – Rapidly progressive nephritic syndrome
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data